Advertisement
Canada markets closed

  • S&P/TSX

    21,969.24
    +83.86 (+0.38%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CAD/USD

    0.7316
    -0.0007 (-0.09%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • Bitcoin CAD

    87,292.70
    -734.16 (-0.83%)
     

  • CMC Crypto 200

    1,327.16
    -69.38 (-4.97%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • RUSSELL 2000

    2,002.00
    +20.88 (+1.05%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,927.90
    +316.14 (+2.03%)
     

  • VOLATILITY

    15.03
    -0.34 (-2.21%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     

Company News For Nov 12, 2019

Zacks Equity Research

  • Qurate Retail Inc.’s QRTEA shares jumped 11.4% after the company reported third-quarter 2019 adjusted earnings per share of $0.42, beating the Zacks Consensual Estimate of $034.

  • Amicus Therapeutics Inc. FOLD surged 3.8% after the company posted third-quarter 2019 total revenue of $48.8 million, surpassing the Zacks Consensus Estimate of $48.1 million.

  • Shares of Nektar Therapeutics NKTR soared 4.7% following positive clinical trial data of its drug NKTR-358 to treat autoimmune and inflammatory diseases.

  • Walgreens Boots Alliance Inc. WBA shares climbed 5.1% following news that KKR & Co. Inc. KKR has decided to acquire the drugstore giant.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
KKR & Co. Inc. (KKR) : Free Stock Analysis Report
 
Amicus Therapeutics, Inc. (FOLD) : Free Stock Analysis Report
 
Nektar Therapeutics (NKTR) : Free Stock Analysis Report
 
Walgreens Boots Alliance, Inc. (WBA) : Free Stock Analysis Report
 
Qurate Retail Group, Inc. (QRTEA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research